• Lipocine dosed the first participant in BLOOM, a Phase 3 trial of LPCN 1154 for postpartum depression.
• The oral brexanolone treatment is being developed as a 48-hour course for at-home use.
• The placebo-controlled outpatient trial plans to enroll approximately 120 participants, with topline results expected in the second half of 2027.
• A previous Phase 3 trial missed its primary endpoint; safety outcomes and exploratory findings supported further evaluation.
• BLOOM incorporates tighter study controls following FDA feedback, aiming to support a potential New Drug Application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050842), on November 10, 2026, and is solely responsible for the information contained therein.